StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.56+0.05 (+0.67%)

Close on Nov 20, 2026Market cap $43.72MP/E –Yield –

Xilio Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Xilio Therapeutics

Xilio Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Xilio Therapeutics figures

See a number that looks wrong?